Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement
- PMID: 35485166
- DOI: 10.1111/cea.14137
Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement
Keywords: Peanut allergy; health-related quality of life; oral immunotherapy; probiotic and peanut oral immunotherapy; sustained unresponsiveness.
References
REFERENCES
-
- Wang Y, Peters RL, Perrett KP, et al. Community-based adverse food reactions and anaphylaxis in children with IgE-mediated food allergy at age 6 years: a population-based study. J Allergy Clin Immunol Pract. 2020;8:3515-3524.
-
- Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394:1437-1449.
-
- Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222-2232.
-
- Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol. 2015;135:737-744.
-
- Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK. PPOIT study Team. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2017;1:97-105.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources